EU says drug firms blocked generics
Posted on: Friday, 28 November 2008, 12:01 CST
The European Commission has accused drug companies of blocking the entry of cheaper generic drugs into Europe, adding billions to the cost of medicine.
In a report from Brussels, the EU said anti-competitive practices ranged from initiating lawsuits to hold up competing products to filing multiple patent applications for the same medicine.
In one case of patent clustering,
the report cited 1,300 patents filed for a single medicine, the Financial Times said.
Patent litigation cases involving generics, meanwhile, lasted an average of nearly three years.
Although the report does not name individual companies, Neelie Kroes, EU competition commissioner, said there likely would be follow-up action against those that had breached EU laws.
Source: United Press International
Related Articles
- Bristol-Myers Squibb to Sell Erbitux in Canada
- Canada's Untapped Access to Medicines Program to Export First AIDS Drug
- The Market for Chinese Traditional Patent Medicine Increased By 10.06% to Total RMB 37.205 Billion
- Philippines Trying to Cut Medicine Cost
- Battling Bacteria in Biotech Start-Up
- Jordanian Firm Plans Pounds 500m London Float
- U.S. should OK generic bird flu drug imports-group
- US should OK generic birdflu drug imports: group
- The Wto Medicines Decision: World Pharmaceutical Trade and the Protection of Public Health
- Folk Medicine in Southern Appalachia
 |
 |
User Comments (0)
RSS Feeds